52 citations
,
January 2005 in “PubMed” This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.
49 citations
,
August 2009 in “British Journal of Cancer” This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.
15 citations
,
November 2015 in “Pharmacopsychiatry” This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.
11 citations
,
August 2014 in “Current Urology Reports” This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.
9 citations
,
July 2003 in “International Journal of Clinical Practice” This study found no significant difference between alpha-blockers and finasteride in contributing to erectile dysfunction among men with other risk factors, with age and other underlying conditions being stronger influences.
8 citations
,
January 2011 in “Korean Journal of Andrology” This study found that combining 4 mg doxazosin with 0.2 mg tamsulosin improved urinary symptoms with fewer vasodilatory side effects compared to a higher dose of doxazosin in hypertensive males with LUTS.
6 citations
,
July 2021 in “Uro” This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.
3 citations
,
March 2013 in “International Journal of Clinical Practice” Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.
3 citations
,
February 1985 in “PubMed” This report describes a case in which the use of the beta-blocker nadolol was associated with infiltrative dermatitis and significant alopecia, which resolved and resulted in total hair regrowth after discontinuation of the drug.
2 citations
,
April 2024 in “Urology Annals” Taking dutasteride every other day works as well as daily and better preserves sexual function.
2 citations
,
February 2023 in “Urology” This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.
This study identified distinct and significant adverse event patterns across different drug classes used to treat benign prostatic hyperplasia, confirming known risks and suggesting novel safety signals for further investigation.
This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.
February 2026 in “Cureus” In this case report, a 25-year-old transgender woman on testosterone-blocking therapy developed generalised hypertrichosis after starting ciclosporin for severe plaque psoriasis, illustrating that ciclosporin can induce this side effect even under androgen suppression.
December 2025 in “International Neurourology Journal” This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.
November 2025 in “Biomedicine & Pharmacotherapy” This study found that administering calcium blockers verapamil or nimodipine significantly preserved auditory function and hair cell survival in Cx26-cKO mice, suggesting potential protective effects for other inner ear disorders.
May 2025 in “Orphanet Journal of Rare Diseases” This review suggests that immunomodulators, including TNF-α blockers and IL inhibitors, may improve symptoms of moderate-to-severe dissecting cellulitis of the scalp, but their effects on hair regrowth and scarring remain unclear.
January 2019 in “Urology Practice” This study observed that urologists are more likely than primary care physicians to prescribe a variety of alpha blockers and newer medications, indicating a broader awareness of treatment options for benign prostate enlargement.
March 2014 in “Annals of Internal Medicine” This review found that adding α1-blockers to 5α-reductase inhibitors may improve lower urinary tract symptoms in men with non-neurogenic conditions, based on existing evidence.
September 2003 in “Reactions Weekly” 
August 2024 in “Journal of Personalized Medicine” In this study using a rabbit model, higher incidences of intraoperative floppy iris syndrome were observed in animals given the α-blocker tamsulosin, suggesting a potential association with increased iris billowing during eye surgery.
61 citations
,
June 2010 in “Journal of the European Academy of Dermatology and Venereology” This study highlights cases of alopecia areata that developed during anti-TNF-α therapy, suggesting a potential link or increased frequency, particularly among individuals with a personal or family history of autoimmune diseases.
22 citations
,
April 1985 in “Australasian Journal of Dermatology” This review discusses the uncommon but potentially serious cutaneous reactions to beta-adrenergic blockers and the uncertain pathogenesis, with no new clinical results reported.
6 citations
,
April 2014 in “European journal of medicinal chemistry” This study found that several newly synthesized dihydrobenzopyran compounds inhibited insulin secretion and had vasorelaxant activity, with some more potent than reference KATP channel activators, though compound 21 functioned as a Ca2+ entry blocker.
3 citations
,
May 2020 in “JAAD Case Reports” This report discusses two patients with plaque psoriasis who developed hypertrichosis, or excessive hair growth, while undergoing interleukin-17A inhibitor therapy.
1 citations
,
March 2009 in “The Journal of Urology” This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.
March 2026 in “The Aging Male” This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.
August 2025 in “Biomedicines” In this case report, half-siblings with bullous congenital ichthyosiform erythroderma were found to have a susceptibility to Trichophyton rubrum infection, successfully treated with oral terbinafine.
July 2015 in “Pharmacological Reports” Finasteride weakens the bone-protective effects of certain blockers in low androgen conditions.
July 2009 in “Guoji yiyao weisheng daobao” This study found that combining α 1A-blockers with Prozac was more effective for treating premature ejaculation than using Prozac alone.